Carlos A. Gongora

ORCID: 0000-0002-0383-2086
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Coronary Interventions and Diagnostics
  • Cardiac Imaging and Diagnostics
  • Cardiovascular Disease and Adiposity
  • Peripheral Artery Disease Management
  • Cardiac Valve Diseases and Treatments
  • Acute Myocardial Infarction Research
  • Cancer Immunotherapy and Biomarkers
  • Cardiovascular Function and Risk Factors
  • Cardiac Structural Anomalies and Repair
  • Pericarditis and Cardiac Tamponade
  • Chemotherapy-induced cardiotoxicity and mitigation
  • Cerebrovascular and Carotid Artery Diseases
  • Infective Endocarditis Diagnosis and Management
  • Heart Failure Treatment and Management
  • Vascular Procedures and Complications
  • Health Systems, Economic Evaluations, Quality of Life
  • Cardiac tumors and thrombi
  • Ultrasound in Clinical Applications
  • Advanced X-ray and CT Imaging
  • Pancreatitis Pathology and Treatment
  • Inflammatory Biomarkers in Disease Prognosis
  • Blood Pressure and Hypertension Studies
  • Atrial Fibrillation Management and Outcomes
  • Lipoproteins and Cardiovascular Health
  • Healthcare Policy and Management

Albert Einstein College of Medicine
2022-2025

Montefiore Medical Center
2022-2024

Northwell Health
2024

Montefiore Health System
2020-2024

British Heart Foundation
2024

Massachusetts General Hospital
2021-2023

The Bronx Defenders
2023

Semmelweis University
2023

Harvard University
2022

St. Vincent's Medical Center
2017-2020

Background There are limited data on the occurrence, associations and outcomes of pericardial effusions pericarditis or after treatment with immune checkpoint inhibitors (ICIs). Methods This was a retrospective study at single academic center that compared 2842 consecutive patients who received ICIs 2699 age- cancer-type matched metastatic disease did not receive ICI. A event defined as composite outcome new worsening moderate large effusion. The endpoints were obtained through chart review...

10.1136/jitc-2021-002771 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2021-06-01

Patients with lung cancer face a heightened risk of atherosclerosis-related cardiovascular events. Despite the strong scientific rationale, there is currently lack clinical evidence examining impact immune checkpoint inhibitors (ICIs) on advancement atherosclerosis in patients cancer. The objective our study was to investigate whether correlation between ICIs and accelerated progression among individuals

10.1136/jitc-2023-007307 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2023-07-01

Background: Rare (monogenic) variants linked to non-ischemic dilated cardiomyopathy (DCM) are enriched among individuals with peripartum (PPCM), alcohol-induced (ALCM), and cancer therapy-related (CCM) cardiomyopathies, but present in less than 15% of cases. Whether a common variant (polygenic) predisposition DCM also pervades these secondary cardiomyopathies remains unclear. Methods: We evaluated the association polygenic score PPCM, ALCM, CCM Mass General Brigham (MGB) Biobank (n =...

10.1101/2025.02.17.25321705 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2025-02-23

Background Cardiotoxicity in patients with cancer treated anthracyclines is associated increased morbidity and mortality. We aimed to examine the incidence of risk factors for cardiotoxicity a racially ethnically diverse cohort anthracyclines. Methods included consecutive adult who underwent anthracycline‐based chemotherapy from 2016 2019 any type cancer. The end point was development (defined as clinical heart failure or drop left ventricular ejection fraction ≥10% ≤50%). Results A total...

10.1161/jaha.124.037780 article EN cc-by-nc-nd Journal of the American Heart Association 2025-03-19

Background Allostatic load (AL) is a measurement of physiological burden chronic stress, operationalized using composite score derived from biomarkers multiple physiologic systems. The relationship between AL and anthracycline cardiotoxicity unclear. Methods Results We included consecutive adult patients who underwent anthracycline‐based chemotherapy 2016 to 2019 for any type cancer. Patients with preexisting heart failure lack measures were excluded the analysis. A was calculated 9 tested...

10.1161/jaha.124.036649 article EN cc-by-nc-nd Journal of the American Heart Association 2025-03-27

The efficacy of paclitaxel-coated balloons (PCB) for the treatment superficial femoral artery (SFA) disease has been demonstrated in clinical setting. Due to high frequency arterial calcification found this vascular territory, adjunctive use atherectomy plus PCB proposed. In study, we aimed evaluate biological effect on healing and drug retention combination approach familial hypercholesterolaemic swine (FHS) model stenosis.Eleven arteries (six five profunda arteries) were included. Vessels...

10.4244/eijy14m10_03 article EN EuroIntervention 2014-12-01

Background Coronary vasospasm is a known side effect of 5-FU (fluorouracil) therapy. Beyond switching to non-5FU-based chemotherapy, there are no established treatments for associated coronary vasospam. Our objective was assess the safety and efficacy re-challenge with after pre-treatment calcium channel blockers (CCBs) long-acting nitrates among patients vasospasm. Methods We conducted retrospective study at single academic center. By protocol, those referred cardio-oncology received either...

10.1371/journal.pone.0265767 article EN cc-by PLoS ONE 2022-04-07

The vascular healing profile of polymers used in bioresorbable scaffolds (BRS) has not been fully characterised the absence antiproliferative drugs. In this study, we aimed to compare polymer biocompatibility and response a novel ultrahigh molecular weight amorphous PLLA BRS (FORTITUDE®; Amaranth Medical, Mountain View, CA, USA) against bare metal stent (BMS) controls porcine coronary arteries.Following device implantation, optical coherence tomography (OCT) evaluation was performed at 0 28...

10.4244/eij-d-16-00308 article EN EuroIntervention 2016-12-01

This study aims to evaluate the efficacy of Pooled Cohort Equation (PCE), U.S. Preventative Services Task Force (USPSTF), and Framingham Risk Score (FRS) models in predicting ASCVD events among patients receiving radiation therapy (RT) for head neck cancer (HNCA). From a large cohort HNCA treated with RT, were adjudicated. Observed vs. predicted compared. We compared rates by statin eligibility status. Regression survival analysis used identify relationship between risk post-RT outcomes....

10.3390/cancers14153651 article EN Cancers 2022-07-27
Coming Soon ...